History of OGT

2009: OGT acqires Sense Proteomic Limited to develop biomarker discovery business 2008: Single cell programme joins EuroSystem consortium; WTCCC project - world’s largest CNV study 2007: Tim Cook appointment; CytoSure™ launch 2006: OGT launches its first microarray product. Appointment of Dr John Anson as Research and Development Director 2005: Appointment of Dr Mike Evans as Chief Executive and Mr James Clough as Commercial Director. Dr David Owen appointed to board as a Non-Executive Director. 2003: Oxford Gene Technology Services Business Unit established to enable access to DNA Microarrays by providing a complete end-to-end service from protocol consultation to data interpretation. 2003: Oxamer Business Unit established to develop and commercialise fabrication methods based on electrochemical (in-situ) synthesis and real time image processing at the molecular level. 2002: Tridend Technologies Business Unit founded to develop and commercialise new chemistries for protein and genomics technologies. 2002: Licensing and Patents Business Unit established; responsible for protecting OGT's intellectual property and out and in-licensing activities. 1999: OGT establishes Oxford Gene Technology (Operations) Limited. 1997: Microarray patents assigned from Oxford University (Isis) to OGT. 1997: First US patent (US5700637) for DNA microarrays granted. 1995: Oxford Gene Technology Limited founded by Professor Edwin Southern to exploit patented technology developed in his research laboratories at Oxford University. 1994: European Patent Specification (EP0373203) for DNA microarrays granted. 1991: First license of fundamental DNA microarray patents issued. 1988: First Patents applied for DNA Microarrays.